Moderate-to-Severe Ulcerative Colitis in Adults: What to Do When Extended Induction Does Not Achieve Remission

This protocol covers adult outpatients with moderate-to-severe ulcerative colitis who were initially naive to advanced therapies and completed an extended induction course, but did not reach clinical response or remission by week 16.

Clinical Scenario

Adult outpatients with moderate-to-severe UC (Mayo Clinic score 6–12) who had no prior exposure to advanced therapies. Clinical remission is most consistently defined as a Mayo Clinic score below 3, with no individual subscore above 1.

Prior Treatment — Failure Condition

An extended induction regimen or dose escalation of the initial advanced agent was attempted for up to 16 weeks in response to an incomplete initial response. The trigger for this protocol is failure to achieve clinical response or clinical remission by the end of that extended induction period.

Next-Line Approach — Partial Overview

The evidence-based approach at this stage involves switching to an advanced therapy with a different mechanism of action from the one that failed.

Full agent selection, sequencing, and supporting evidence are in the complete protocol below.

Treatment Targets

Symptomatic response within 3 months of initiating the new therapy; symptomatic and biochemical remission within 3–6 months; endoscopic improvement or remission within 6–12 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1053/j.gastro.2024.10.001

In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a LOWER efficacy medication (adalimumab).

Scores of 6–12 correspond to moderate-to-severe disease activity, whereas clinical remission is most consistently defined as Mayo Clinic score <3, with no individual subscore >1.

In adult outpatients with moderate-to-severe UC who have previously been exposed to 1 or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).

Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 mo of initiation, symptomatic and biochemical remission within 3–6 mo, and endoscopic improvement/remission within 6–12 mo.

View source ↗